Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05724199




Registration number
NCT05724199
Ethics application status
Date submitted
2/02/2023
Date registered
13/02/2023
Date last updated
27/09/2024

Titles & IDs
Public title
A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD)
Scientific title
A Phase 3, Randomized, 24-week, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab (AMG 451) in Combination With Topical Corticosteroids and/or Topical Calcineurin Inhibitors in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-SHUTTLE)
Secondary ID [1] 0 0
2022-501585-22
Secondary ID [2] 0 0
20210144
Universal Trial Number (UTN)
Trial acronym
ROCKET-SHUTTLE
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Atopic Dermatitis 0 0
Condition category
Condition code
Skin 0 0 0 0
Dermatological conditions
Skin 0 0 0 0
Other skin conditions
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Rocatinlimab
Other interventions - Placebo

Experimental: Rocatinlimab Dose 1 + TCS/TCI - Rocatinlimab Dose 1 every 4 weeks (Q4W) for 24 weeks + TCS/TCI + loading dose at Week 2.

Experimental: Rocatinlimab Dose 2 + TCS/TCI - Rocatinlimab Dose 2 Q4W for 24 weeks + TCS/TCI + loading dose at Week 2.

Placebo comparator: Placebo + TCS/TCI - Placebo Q4W for 24 weeks + TCS/TCI + loading dose at Week 2.


Treatment: Drugs: Rocatinlimab
Subcutaneous (SC) injection

Other interventions: Placebo
SC injection
Intervention code [1] 0 0
Treatment: Drugs
Intervention code [2] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Achievement of a vIGA-AD Score of 0 or 1 with a =2 Point Reduction From Baseline at Week 24
Timepoint [1] 0 0
Baseline, Week 24
Primary outcome [2] 0 0
Achievement of = 75% Reduction From Baseline in EASI Score (EASI 75) at Week 24
Timepoint [2] 0 0
Baseline, Week 24
Secondary outcome [1] 0 0
Achievement of EASI 75 at Week 16
Timepoint [1] 0 0
Baseline, Week 16
Secondary outcome [2] 0 0
Achievement of vIGA-AD 0/1 at Week 16
Timepoint [2] 0 0
Baseline, Week 16
Secondary outcome [3] 0 0
Achievement of a = 4-point Reduction From Baseline in Weekly Average of Daily Worst Pruritus Numeric Rating Scale (NRS) Score at Week 16 in Participants with Baseline Weekly Average of Daily Worst Pruritus NRS Score = 4
Timepoint [3] 0 0
Baseline, Week 16
Secondary outcome [4] 0 0
Achievement of a = 4-point Reduction From Baseline in Weekly Average of Daily Worst Pruritus NRS Score at Week 24 in Participants with Baseline Weekly Average of Daily Worst Pruritus NRS Score = 4
Timepoint [4] 0 0
Baseline, Week 24
Secondary outcome [5] 0 0
Achievement of = 90% Reduction From Baseline in EASI Score (EASI 90) at Week 24
Timepoint [5] 0 0
Baseline, Week 24
Secondary outcome [6] 0 0
Achievement of a = 4-point Reduction From Baseline in Weekly Average of AD Skin Pain NRS Score at Week 24 in Participants With Baseline Weekly Average of AD Skin Pain NRS Score = 4
Timepoint [6] 0 0
Baseline, Week 24
Secondary outcome [7] 0 0
Achievement of vIGA-AD 1 Response with a Presence of Only Barely Perceptible Erythema or vlGA-AD 0 Response (Revised IGA [rIGA™] 0/1) at Week 24
Timepoint [7] 0 0
Baseline, Week 24
Secondary outcome [8] 0 0
Achievement of a Facial AD Severity Score of Clear at Week 24 for Participants with Facial AD at Baseline
Timepoint [8] 0 0
Baseline, Week 24
Secondary outcome [9] 0 0
Achievement of a Hand AD Severity Score of Clear at Week 24 for Participants with Hand AD at Baseline
Timepoint [9] 0 0
Baseline, Week 24
Secondary outcome [10] 0 0
Change From Baseline in Weekly Average of Daily Worst Pruritus NRS Score at Week 16
Timepoint [10] 0 0
Baseline, Week 16
Secondary outcome [11] 0 0
Change From Baseline in Weekly Average of Daily Worst Pruritus NRS Score at Week 24
Timepoint [11] 0 0
Baseline, Week 24
Secondary outcome [12] 0 0
Change From Baseline in SCORing Atopic Dermatitis (SCORAD) Itch Visual Analogue Scale (VAS) Score at Week 16
Timepoint [12] 0 0
Baseline, Week 16
Secondary outcome [13] 0 0
Change From Baseline in SCORAD Itch VAS Score at Week 24
Timepoint [13] 0 0
Baseline, Week 24
Secondary outcome [14] 0 0
Achievement of = 4-point Reduction From Baseline in Dermatology Life Quality Index (DLQI) Score at Week 24 in Participants With Baseline DLQI Score = 4
Timepoint [14] 0 0
Baseline, Week 24
Secondary outcome [15] 0 0
Change from Baseline in DLQI Score at Week 24
Timepoint [15] 0 0
Baseline, Week 24
Secondary outcome [16] 0 0
Achievement of a = 4-point Reduction From Baseline in Patient Oriented Eczema Measure (POEM) Score at Week 24 in Participants with Baseline POEM Score = 4
Timepoint [16] 0 0
Baseline, Week 24
Secondary outcome [17] 0 0
Change From Baseline in POEM Score at Week 24
Timepoint [17] 0 0
Baseline, Week 24
Secondary outcome [18] 0 0
Achievement of a = 4-point Reduction From Baseline in Weekly Average of AD Skin Pain NRS Score at Week 16 in Participants With Baseline Weekly Average of AD skin pain NRS Score = 4
Timepoint [18] 0 0
Baseline, Week 16
Secondary outcome [19] 0 0
Change From Baseline in Weekly Average of Daily AD Skin Pain NRS Score at Week 24
Timepoint [19] 0 0
Baseline, Week 24
Secondary outcome [20] 0 0
Change From Baseline in Weekly Average of Daily AD Skin Pain NRS Score at Week 16
Timepoint [20] 0 0
Baseline, Week 16
Secondary outcome [21] 0 0
Achievement of a = 3-point Reduction From Baseline in Weekly Average of AD Skin Pain NRS Score at Week 24 in Participants With Baseline Weekly Average of AD Skin Pain NRS Score = 3
Timepoint [21] 0 0
Baseline, Week 24
Secondary outcome [22] 0 0
Achievement of a = 3-point Reduction From Baseline in Weekly Average of AD Skin Pain NRS Score at Week 16 in Participants With Baseline Weekly Average of AD Skin Pain NRS Score = 3
Timepoint [22] 0 0
Baseline, Week 16
Secondary outcome [23] 0 0
Change From Baseline in Weekly Average of Sleep Disturbance NRS Score at Week 24
Timepoint [23] 0 0
Baseline, Week 24
Secondary outcome [24] 0 0
Achievement of a Hospital Anxiety and Depression Scale (HADS)-anxiety Subscale Score < 8 at Week 24 in Participants with Baseline HADS-anxiety Subscale Score = 8
Timepoint [24] 0 0
Baseline, Week 24
Secondary outcome [25] 0 0
Achievement of a HADS-depression Subscale Score < 8 at Week 24 in Participants with Baseline HADS-depression Subscale Score = 8
Timepoint [25] 0 0
Baseline, Week 24
Secondary outcome [26] 0 0
Change From Baseline in HADS-anxiety Subscale Score at Week 24
Timepoint [26] 0 0
Baseline, Week 24
Secondary outcome [27] 0 0
Change From Baseline in HADS-depression Subscale Score at Week 24
Timepoint [27] 0 0
Baseline, Week 24
Secondary outcome [28] 0 0
Achievement of a = 8.7-point Reduction from Baseline in SCORAD Score at Week 24 in Participants with Baseline SCORAD Score = 8.7
Timepoint [28] 0 0
Baseline, Week 24

Eligibility
Key inclusion criteria
* Age = 18 years with a diagnosis of AD according to the AAD (American Academy of Dermatology) Consensus Criteria (2014) present for at least 12 months
* History of inadequate response to TCS of medium or higher potency (with or without TCI)
* EASI score =16
* vIGA-AD score =3
* =10% body surface area (BSA) of AD involvement
* Worst pruritus numerical rating scale = 4
Minimum age
18 Years
Maximum age
100 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Treatment with a biological product within 12 weeks or 5 half-lives, whichever is longer, prior to Day 1
* Treatment with any of the following medications or therapies within 4 weeks or 5 half-lives, whichever is longer, prior to Day 1:

* Systemic corticosteroids
* Nonbiologic, non-targeted Systemic immunosuppressants
* Phototherapy
* Janus kinase inhibitors
* Treatment with any of the following medications or therapies within 1 week, prior to Day 1:

* TCS
* TCI
* Topical phosphodiesterase type 4 inhibitors
* Other topical immunosuppressive agents
* Combination topical agents including TCS of any potency or TCI, PDE4 inhibitors, or other topical immunosuppressive agents

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Other
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
21/02/2023
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
9/12/2024
Actual
Sample size
Target
Accrual to date
Final
746
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Recruitment hospital [1] 0 0
Emeritus Research Sydney - Botany
Recruitment hospital [2] 0 0
Westmead Hospital - Westmead
Recruitment hospital [3] 0 0
The Skin Centre - Benowa
Recruitment hospital [4] 0 0
Princess Alexandra Hospital - South Brisbane
Recruitment hospital [5] 0 0
Veracity Clinical Research - Woolloongabba
Recruitment hospital [6] 0 0
Emeritus Research Melbourne - Camberwell
Recruitment postcode(s) [1] 0 0
2019 - Botany
Recruitment postcode(s) [2] 0 0
2145 - Westmead
Recruitment postcode(s) [3] 0 0
4217 - Benowa
Recruitment postcode(s) [4] 0 0
4101 - South Brisbane
Recruitment postcode(s) [5] 0 0
4102 - Woolloongabba
Recruitment postcode(s) [6] 0 0
3124 - Camberwell
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
Arkansas
Country [4] 0 0
United States of America
State/province [4] 0 0
California
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Georgia
Country [7] 0 0
United States of America
State/province [7] 0 0
Illinois
Country [8] 0 0
United States of America
State/province [8] 0 0
Indiana
Country [9] 0 0
United States of America
State/province [9] 0 0
Kansas
Country [10] 0 0
United States of America
State/province [10] 0 0
Louisiana
Country [11] 0 0
United States of America
State/province [11] 0 0
Maryland
Country [12] 0 0
United States of America
State/province [12] 0 0
Michigan
Country [13] 0 0
United States of America
State/province [13] 0 0
Nebraska
Country [14] 0 0
United States of America
State/province [14] 0 0
Nevada
Country [15] 0 0
United States of America
State/province [15] 0 0
New Jersey
Country [16] 0 0
United States of America
State/province [16] 0 0
New Mexico
Country [17] 0 0
United States of America
State/province [17] 0 0
New York
Country [18] 0 0
United States of America
State/province [18] 0 0
North Carolina
Country [19] 0 0
United States of America
State/province [19] 0 0
Ohio
Country [20] 0 0
United States of America
State/province [20] 0 0
Oregon
Country [21] 0 0
United States of America
State/province [21] 0 0
Pennsylvania
Country [22] 0 0
United States of America
State/province [22] 0 0
South Dakota
Country [23] 0 0
United States of America
State/province [23] 0 0
Texas
Country [24] 0 0
United States of America
State/province [24] 0 0
Virginia
Country [25] 0 0
Argentina
State/province [25] 0 0
Buenos Aires
Country [26] 0 0
Argentina
State/province [26] 0 0
Distrito Federal
Country [27] 0 0
Argentina
State/province [27] 0 0
Santa Fe
Country [28] 0 0
Austria
State/province [28] 0 0
Graz
Country [29] 0 0
Austria
State/province [29] 0 0
Innsbruck
Country [30] 0 0
Austria
State/province [30] 0 0
Salzburg
Country [31] 0 0
Austria
State/province [31] 0 0
Wien
Country [32] 0 0
Belgium
State/province [32] 0 0
Brugge
Country [33] 0 0
Belgium
State/province [33] 0 0
Brussels
Country [34] 0 0
Belgium
State/province [34] 0 0
Brussel
Country [35] 0 0
Belgium
State/province [35] 0 0
Bruxelles
Country [36] 0 0
Belgium
State/province [36] 0 0
Gent
Country [37] 0 0
Belgium
State/province [37] 0 0
Herstal
Country [38] 0 0
Belgium
State/province [38] 0 0
Kortrijk
Country [39] 0 0
Belgium
State/province [39] 0 0
Leuven
Country [40] 0 0
Belgium
State/province [40] 0 0
Liege
Country [41] 0 0
Belgium
State/province [41] 0 0
Loverval
Country [42] 0 0
Bulgaria
State/province [42] 0 0
Dupnitsa
Country [43] 0 0
Bulgaria
State/province [43] 0 0
Pleven
Country [44] 0 0
Bulgaria
State/province [44] 0 0
Sofia
Country [45] 0 0
Canada
State/province [45] 0 0
Alberta
Country [46] 0 0
Canada
State/province [46] 0 0
British Columbia
Country [47] 0 0
Canada
State/province [47] 0 0
Manitoba
Country [48] 0 0
Canada
State/province [48] 0 0
Ontario
Country [49] 0 0
Canada
State/province [49] 0 0
Quebec
Country [50] 0 0
Canada
State/province [50] 0 0
Saskatchewan
Country [51] 0 0
China
State/province [51] 0 0
Beijing
Country [52] 0 0
China
State/province [52] 0 0
Fujian
Country [53] 0 0
China
State/province [53] 0 0
Guangdong
Country [54] 0 0
China
State/province [54] 0 0
Henan
Country [55] 0 0
China
State/province [55] 0 0
Hubei
Country [56] 0 0
China
State/province [56] 0 0
Jiangsu
Country [57] 0 0
China
State/province [57] 0 0
Jiangxi
Country [58] 0 0
China
State/province [58] 0 0
Jilin
Country [59] 0 0
China
State/province [59] 0 0
Sichuan
Country [60] 0 0
China
State/province [60] 0 0
Zhejiang
Country [61] 0 0
China
State/province [61] 0 0
Shanghai
Country [62] 0 0
France
State/province [62] 0 0
Antony
Country [63] 0 0
France
State/province [63] 0 0
Bordeaux
Country [64] 0 0
France
State/province [64] 0 0
Brest
Country [65] 0 0
France
State/province [65] 0 0
Lille
Country [66] 0 0
France
State/province [66] 0 0
Lorient Cedex
Country [67] 0 0
France
State/province [67] 0 0
Marseille cedex 05
Country [68] 0 0
France
State/province [68] 0 0
Martigues
Country [69] 0 0
France
State/province [69] 0 0
Nantes
Country [70] 0 0
France
State/province [70] 0 0
Nice
Country [71] 0 0
France
State/province [71] 0 0
Paris Cedex 10
Country [72] 0 0
France
State/province [72] 0 0
Paris
Country [73] 0 0
France
State/province [73] 0 0
Reims
Country [74] 0 0
France
State/province [74] 0 0
Rennes Cedex 9
Country [75] 0 0
France
State/province [75] 0 0
Rouen Cedex
Country [76] 0 0
France
State/province [76] 0 0
Saint Priest en Jarez
Country [77] 0 0
France
State/province [77] 0 0
Toulon
Country [78] 0 0
Germany
State/province [78] 0 0
Frankfurt am Main
Country [79] 0 0
Germany
State/province [79] 0 0
Goettingen
Country [80] 0 0
Germany
State/province [80] 0 0
Hamburg
Country [81] 0 0
Germany
State/province [81] 0 0
Hannover
Country [82] 0 0
Germany
State/province [82] 0 0
Mainz
Country [83] 0 0
Germany
State/province [83] 0 0
Memmingen
Country [84] 0 0
Germany
State/province [84] 0 0
Merzing
Country [85] 0 0
Germany
State/province [85] 0 0
Muenchen
Country [86] 0 0
Greece
State/province [86] 0 0
Athens
Country [87] 0 0
Greece
State/province [87] 0 0
Heraklion
Country [88] 0 0
Greece
State/province [88] 0 0
Nea Ionia
Country [89] 0 0
Greece
State/province [89] 0 0
Piraeus
Country [90] 0 0
Greece
State/province [90] 0 0
Thessaloniki
Country [91] 0 0
Hungary
State/province [91] 0 0
Bekescsaba
Country [92] 0 0
Hungary
State/province [92] 0 0
Budapest
Country [93] 0 0
Hungary
State/province [93] 0 0
Debrecen
Country [94] 0 0
Hungary
State/province [94] 0 0
Gyongyos
Country [95] 0 0
Hungary
State/province [95] 0 0
Kaposvar
Country [96] 0 0
Hungary
State/province [96] 0 0
Oroshaza
Country [97] 0 0
Hungary
State/province [97] 0 0
Szolnok
Country [98] 0 0
Hungary
State/province [98] 0 0
Zalaegerszeg
Country [99] 0 0
Italy
State/province [99] 0 0
Genova
Country [100] 0 0
Italy
State/province [100] 0 0
LAquila
Country [101] 0 0
Italy
State/province [101] 0 0
Roma
Country [102] 0 0
Italy
State/province [102] 0 0
Rozzano MI
Country [103] 0 0
Japan
State/province [103] 0 0
Aichi
Country [104] 0 0
Japan
State/province [104] 0 0
Fukuoka
Country [105] 0 0
Japan
State/province [105] 0 0
Hokkaido
Country [106] 0 0
Japan
State/province [106] 0 0
Kagoshima
Country [107] 0 0
Japan
State/province [107] 0 0
Kanagawa
Country [108] 0 0
Japan
State/province [108] 0 0
Kumamoto
Country [109] 0 0
Japan
State/province [109] 0 0
Osaka
Country [110] 0 0
Japan
State/province [110] 0 0
Shizuoka
Country [111] 0 0
Japan
State/province [111] 0 0
Tokyo
Country [112] 0 0
Malaysia
State/province [112] 0 0
Johor
Country [113] 0 0
Malaysia
State/province [113] 0 0
Perak
Country [114] 0 0
Malaysia
State/province [114] 0 0
Pinang
Country [115] 0 0
Malaysia
State/province [115] 0 0
Sabah
Country [116] 0 0
Malaysia
State/province [116] 0 0
Wilayah Persekutuan
Country [117] 0 0
Netherlands
State/province [117] 0 0
Bergen op Zoom
Country [118] 0 0
Netherlands
State/province [118] 0 0
Groningen
Country [119] 0 0
Netherlands
State/province [119] 0 0
Utrecht
Country [120] 0 0
Poland
State/province [120] 0 0
Chorzow
Country [121] 0 0
Poland
State/province [121] 0 0
Katowice
Country [122] 0 0
Poland
State/province [122] 0 0
Krakow
Country [123] 0 0
Poland
State/province [123] 0 0
Lodz
Country [124] 0 0
Poland
State/province [124] 0 0
Szczecin
Country [125] 0 0
Poland
State/province [125] 0 0
Wroclaw
Country [126] 0 0
Puerto Rico
State/province [126] 0 0
Caguas
Country [127] 0 0
Romania
State/province [127] 0 0
Brasov
Country [128] 0 0
Romania
State/province [128] 0 0
Cluj-Napoca
Country [129] 0 0
Romania
State/province [129] 0 0
Targu Mures
Country [130] 0 0
Singapore
State/province [130] 0 0
Singapore
Country [131] 0 0
Slovakia
State/province [131] 0 0
Bardejov
Country [132] 0 0
Slovakia
State/province [132] 0 0
Bratislava
Country [133] 0 0
Slovakia
State/province [133] 0 0
Presov
Country [134] 0 0
Slovakia
State/province [134] 0 0
Svidnik
Country [135] 0 0
Slovenia
State/province [135] 0 0
Ljubljana
Country [136] 0 0
Slovenia
State/province [136] 0 0
Maribor
Country [137] 0 0
Spain
State/province [137] 0 0
Cataluña
Country [138] 0 0
Spain
State/province [138] 0 0
Comunidad Valenciana
Country [139] 0 0
Spain
State/province [139] 0 0
País Vasco
Country [140] 0 0
Spain
State/province [140] 0 0
Madrid
Country [141] 0 0
Spain
State/province [141] 0 0
Pontevedra
Country [142] 0 0
Switzerland
State/province [142] 0 0
Bern
Country [143] 0 0
Switzerland
State/province [143] 0 0
Geneve 14
Country [144] 0 0
Switzerland
State/province [144] 0 0
Lausanne
Country [145] 0 0
Switzerland
State/province [145] 0 0
Sankt Gallen
Country [146] 0 0
Switzerland
State/province [146] 0 0
Zuerich
Country [147] 0 0
Turkey
State/province [147] 0 0
Ankara
Country [148] 0 0
Turkey
State/province [148] 0 0
Istanbul
Country [149] 0 0
Turkey
State/province [149] 0 0
Samsun
Country [150] 0 0
United Kingdom
State/province [150] 0 0
Bath
Country [151] 0 0
United Kingdom
State/province [151] 0 0
Dudley
Country [152] 0 0
United Kingdom
State/province [152] 0 0
Isleworth
Country [153] 0 0
United Kingdom
State/province [153] 0 0
London
Country [154] 0 0
United Kingdom
State/province [154] 0 0
Salford
Country [155] 0 0
United Kingdom
State/province [155] 0 0
Shipley

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Amgen
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The coprimary objectives of the study are to:

* evaluate the efficacy of rocatinlimab in combination with topical corticosteroid and/or topical calcineurin inhibitor (TCS/TCI), compared with placebo in combination with TCS/TCI at Week 24, assessed using Validated Investigator's Global Assessment for Atopic Dermatitis (vIGA-AD™).
* evaluate the efficacy of rocatinlimab, in combination with TCS/TCI, compared with placebo in combination with TCS/TCI at Week 24, assessed using Eczema Area and Severity Index (EASI).
Trial website
https://clinicaltrials.gov/study/NCT05724199
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
MD
Address 0 0
Amgen
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT05724199